BACKGROUND: We retrospectively analyzed our transplant database from July 2000 to June 2012 to identify myeloma patients who received autologous stem cell transplantation while dialysis-dependent. PATIENTS: 2091 patients underwent autologous high-dose therapy during this period. Twenty-four patients were dialysis-dependent. RESULTS: The 100-day and the 6, and 12-month treatment-related mortality was 0%. Overall response rate was 92%. The median progression-free survival and overall survival were 1.9 years and 3.8 years, respectively. A multivariate analysis was not performed because of the small sample size. Only 3 patients became dialysis-independent after transplantation. Cardiac, gastrointestinal, genitourinary, infectious, neurologic, and pulmonary "all grade" toxicities were all higher in the melphalan 200 group versus < 200 group, however, none of them were statistically significant. CONCLUSION: Because of a lack of clear survival benefit with higher-dose melphalan and potential higher toxicity in this group, it is reasonable to use lower-dose melphalan in dialysis-dependent myeloma patients.
BACKGROUND: We retrospectively analyzed our transplant database from July 2000 to June 2012 to identify myelomapatients who received autologous stem cell transplantation while dialysis-dependent. PATIENTS: 2091 patients underwent autologous high-dose therapy during this period. Twenty-four patients were dialysis-dependent. RESULTS: The 100-day and the 6, and 12-month treatment-related mortality was 0%. Overall response rate was 92%. The median progression-free survival and overall survival were 1.9 years and 3.8 years, respectively. A multivariate analysis was not performed because of the small sample size. Only 3 patients became dialysis-independent after transplantation. Cardiac, gastrointestinal, genitourinary, infectious, neurologic, and pulmonary "all grade" toxicities were all higher in the melphalan 200 group versus < 200 group, however, none of them were statistically significant. CONCLUSION: Because of a lack of clear survival benefit with higher-dose melphalan and potential higher toxicity in this group, it is reasonable to use lower-dose melphalan in dialysis-dependent myelomapatients.
Authors: Antonio Palumbo; S Vincent Rajkumar; Jesus F San Miguel; Alessandra Larocca; Ruben Niesvizky; Gareth Morgan; Ola Landgren; Roman Hajek; Hermann Einsele; Kenneth C Anderson; Meletios A Dimopoulos; Paul G Richardson; Michele Cavo; Andrew Spencer; A Keith Stewart; Kazuyuki Shimizu; Sagar Lonial; Pieter Sonneveld; Brian G M Durie; Philippe Moreau; Robert Z Orlowski Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: M A Dimopoulos; S Delimpasi; E Katodritou; A Vassou; M C Kyrtsonis; P Repousis; Z Kartasis; A Parcharidou; M Michael; E Michalis; D Gika; A Symeonidis; A Pouli; K Konstantopoulos; E Terpos; E Kastritis Journal: Ann Oncol Date: 2014-01 Impact factor: 32.976
Authors: B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar Journal: Leukemia Date: 2006-07-20 Impact factor: 11.528
Authors: M A Dimopoulos; M Roussou; M Gkotzamanidou; N Nikitas; E Psimenou; D Mparmparoussi; C Matsouka; M Spyropoulou-Vlachou; E Terpos; E Kastritis Journal: Leukemia Date: 2012-07-05 Impact factor: 11.528
Authors: Qaiser Bashir; Nina Shah; Simrit Parmar; Wei Wei; Gabriela Rondon; Donna M Weber; Michael Wang; Robert Z Orlowski; Sheeba K Thomas; Jatin Shah; Sofia R Qureshi; Yvonne T Dinh; Uday Popat; Paolo Anderlini; Chitra Hosing; Sergio Giralt; Richard E Champlin; Muzaffar H Qazilbash Journal: Leuk Lymphoma Date: 2011-08-24
Authors: Marc S Raab; Iris Breitkreutz; Michael Hundemer; Axel Benner; Jens Klaus; Ute Hegenbart; Thomas Moehler; Anthony D Ho; Martin Zeier; Hartmut Goldschmidt Journal: Haematologica Date: 2006-11 Impact factor: 9.941
Authors: J F San-Miguel; P G Richardson; P Sonneveld; M W Schuster; D Irwin; E A Stadtmauer; T Facon; J-L Harousseau; D Ben-Yehuda; S Lonial; H Goldschmidt; D Reece; J Bladé; M Boccadoro; J D Cavenagh; R Neuwirth; A L Boral; D-L Esseltine; K C Anderson Journal: Leukemia Date: 2008-01-17 Impact factor: 11.528
Authors: Gaurav C Parikh; Ali Imran Amjad; Rima M Saliba; Syed M A Kazmi; Ziad U Khan; Amit Lahoti; Chitra Hosing; Floralyn Mendoza; Suhail R Qureshi; Donna M Weber; Michael Wang; Uday Popat; Amin M Alousi; Richard E Champlin; Sergio A Giralt; Muzaffar H Qazilbash Journal: Biol Blood Marrow Transplant Date: 2009-07 Impact factor: 5.742
Authors: Ala Abudayyeh; Heather Lin; Omar Mamlouk; Maen Abdelrahim; Rima Saliba; Gabriela Rondon; Charles S Martinez; Ruby Delgado; Valda Page; Arun Rajasekaran; Paul W Sanders; Muzaffar Qazilbash Journal: Leuk Lymphoma Date: 2020-07-29
Authors: A Mahindra; P Hari; R Fraser; M Fei; J Huang; J Berdeja; N Callander; L Costa; M A Diaz; C Freytes; R P Gale; S Girnius; L Holmberg; M Kharfan-Dabaja; S Kumar; R Kyle; H Lazarus; C Lee; A Maiolino; J Moreb; T Nishihori; A Pawarode; A Saad; B N Savani; J Schriber; B William; B M Wirk; A Krishnan; Y Nieto; A D'Souza Journal: Bone Marrow Transplant Date: 2017-09-18 Impact factor: 5.483